期刊文献+

CDH5在恶性肿瘤中的研究进展 被引量:2

Research progress of CDH5 in malignant tumors
原文传递
导出
摘要 钙粘蛋白(cadherin,CDH)5,又称血管内皮细胞CDH(vascular endothelial cell-CDH,VE-CDH),是一种内皮细胞特异性膜蛋白。CDH5可促进微血管生成,为肿瘤细胞提供适合的支持微环境,并能促进肿瘤细胞增殖和转移。CDH5与恶性肿瘤发生、发展的各个过程都有密切关系。文章总结了CDH5在多种肿瘤中的研究现状,评估CDH5在促进肿瘤细胞生成、转移及预后的潜力。 Cadherin(CDH)5,also known as vascular endothelial cell CDH(VE-CDH),is an endothelial cell-specific membrane protein.CDH5 can promote angiogenesis,provide a suitable supporting microenvironment for tumor cells,and promote tumor cell proliferation and metastasis.CDH5 is closely related to the occurrence and development of malignant tumors.This review summarizes the research status of CDH5 in various malignant tumors,and to evaluate the potential of CDH5 in promoting tumor cell generation,metastasis and prognosis.
作者 张星海 方天逸 边秀兰 张磊 Zhang Xinghai;Fang Tianyi;Bian Xiulan;Zhang Lei(Department of Pathology,Harbin Medical University,Harbin 150081,China;Department of Gastroenterological Surgery,Harbin Medical University Cancer Hospital,Harbin Medical University,Harbin 150081,China)
出处 《国际免疫学杂志》 CAS 2023年第1期66-70,共5页 International Journal of Immunology
关键词 钙粘蛋白5 恶性肿瘤 增殖 转移 预后评估 Cadherin5 Malignant tumor Proliferation Metastasis Prognostic evaluation
  • 相关文献

参考文献2

二级参考文献26

  • 1Sung J J, Lau JY, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol, 2005, 6( 11 ) :871-876.
  • 2Shah U, Goldberg RM. Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer. Clin Colorectal Cancer, 2008, 7 ( 5 ) : 315-320.
  • 3Tappendlen P, Jones R, Paisley S,et al. Systematic review and economic evacluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess, 2007,11 (12) ,1-128.
  • 4Zlobec I, Vuong T, Hayashi S, et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy. Br J Cancer, 2007, 96(5):793-800.
  • 5Weiner LM, Belldegrun AS, Crawford J, et al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Ctin Cancer Res, 2008, 14(2) :502-508.
  • 6Ramadori G, Cameron S, Tschechne B. Long-Lasting Tumor Response in Patients with Panitunmmab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma-A Report of Two Cases. Case Rep Oncol, 2010, 3(2) :154-159.
  • 7Williams KJ, Lockhart AC. Targeting colorectal cancer with antiepidermal growth factor receptor antibodies: focus on panitumumab. Onco Targets Ther, 2009, 2:161-170.
  • 8Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oneogene, 2000, 19(56) :6550-6565.
  • 9Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer, 2006, 107 (6) : 1207-1218.
  • 10Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs, 2007, 18(1) :7-15.

共引文献7

同被引文献13

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部